A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects with Moderate to severe Hidradenitis Suppurativa
Brief description of study
The primary objective of this study is to evaluate the efficacy of bimekizumab in subjects with
moderate to severe HS.
The secondary objective of this study is to assess the safety, tolerability, immunogenicity, and
PK of bimekizumab in subjects with moderate to severe HS.